Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
Healthcare
$9.47 +1.59%
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
52W Low $3.33High $17.25
Volume 0.32M
Average 0.74M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$54.36M
FY 2025 · Annual
Investing Cash Flow
$22.91M
FY 2025 · Annual
-47.9% YoYFinancing Cash Flow
$25.74M
FY 2025 · Annual
+4917.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Depreciation & Amortization | 129K | 406K | 537K | 596K | (2.63M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.69M | 10.93M | 13.09M | 13.07M | 14.55M |
| Change in Working Capital | 1.4M | 1.99M | 728K | (993K) | 3.11M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.41M | 5.39M | (1.25M) | (1.22M) | 4.49M |
| Other Working Capital | (1.02M) | (3.39M) | 1.97M | 226K | (1.38M) |
| Other Non-Cash Items | (58K) | (1.33M) | (6.05M) | (6.19M) | 406K |
| Operating Cash Flow | (29.38M) | (51.32M) | (58.56M) | (43.11M) | (54.36M) |
| Capital Expenditures | (1.54M) | (918K) | (256K) | (340K) | (193K) |
| Acquisitions (Net) | 52.11K | 39K | 0 | 0 | 0 |
| Purchases of Investments | (86.26M) | (313M) | (224.7M) | (230.18M) | (291.78M) |
| Sales of Investments | 34.16M | 92.89M | 277.5M | 274.47M | 314.89M |
| Other Investing Activities | (52.11K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (53.64M) | (220.99M) | 52.54M | 43.96M | 22.91M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 254.27M | 662K | 724K | 513K | 25.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 228K | (427K) | 0 | 0 | 0 |
| Financing Cash Flow | 379.21M | 235K | 724K | 513K | 25.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 296.19M | (272.07M) | (5.3M) | 1.36M | (5.71M) |
| Free Cash Flow | (30.92M) | (52.24M) | (58.82M) | (43.45M) | (54.55M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$69.8M
+ D&A-$2.6M
+ Stock-Based Comp$14.5M
+ Deferred Tax$0
+ Working Capital$3.1M
+ Other Non-Cash$406.0K
= Operating Cash Flow-$54.4M
- Capex-$193.0K
= Free Cash Flow-$54.6M
Analysis
FY2025 free cash flow is -$54.6M. FCF conversion is 78.2% of net income. Operating cash flow was -$54.4M, with capex of -$193.0K. The largest bridge item is Stock-Based Comp at $14.5M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| EFFECT | EFFECT filing | Nov 12, 2026 | |
| 424B5 | 424B5 filing | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| S-3 | S-3 filing | Nov 4, 2026 |
Does DSGN generate free cash flow?
Design Therapeutics, Inc. (DSGN) generated -$54.55M of free cash flow in fiscal 2025.
How much operating cash flow does DSGN produce?
Operating cash flow was -$54.36M, before capital expenditures of $193,000.00.
Continue the stock analysis
Jump to another research area for this company.